For patients under 55 years old: Papillary thyroid cancer is classified as stage 2 if the cancer has spread to distant parts ...

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.

CONCORD, N.H. — In May, Robb Jutton was so sick, he wasn’t sure he’d be alive for his daughter’s graduation, just a few weeks away. Neither was his doctor, who put Jutton’s odds of making it at about ...

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: ...